Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Zhichao, Li, Feng, Zhang, Chao, Zhu, Lei, Shi, Yehui, Zhao, Gang, Bai, Xu, Hassan, Shafat, Liu, Xinyue, Li, Ting, Xing, Peipei, Zhao, Jun, Zhang, Jin, Xing, Ruwei, Teng, Sheng, Yang, Yun, Chen, Kexin, Yang, Jilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395676/
https://www.ncbi.nlm.nih.gov/pubmed/30816108
http://dx.doi.org/10.1038/s12276-019-0221-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395676/
https://www.ncbi.nlm.nih.gov/pubmed/30816108
http://dx.doi.org/10.1038/s12276-019-0221-7

Ejemplares similares